EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

High Throughput Pharmacovigilance Screening for Roflumilast Adverse Effects in Real‐World Settings: A Sequence Symmetry Analysis

Abdullah Abdelaziz iD, Charles E Gaber, Preeti Gupta, Todd A Lee

Basic & Clinical Pharmacology & Toxicology · 2025

DOI: 10.1111/bcpt.70038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2025. Verfasst von Abdullah Abdelaziz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Systems, Outcomes and Policy, College of Pharmacy, University of Illinois Chicago, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Benzamides, Phosphodiesterase 4 Inhibitors, Pharmacovigilance, Aminopyridines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Roflumilast is an add‐on therapy for COPD following exacerbations, but real‐world safety data in the United States are limited.

Objective

This study aimed to identify safety signals associated with roflumilast initiation through a high‐throughput signal detection algorithm.

Methods

Using sequence symmetry analysis (SSA), we analysed Marketscan databases for new roflumilast users (2011–2021). We screened for adverse effects across 211 therapeutic classes within 365 days of initiation. Sensitivity analyses were conducted by sex, age and observation period. Crude and adjusted sequence ratios (cSR and aSR) were reported with 95% confidence intervals (CIs).

Results

Among 11 091 patients (53% aged 65+, 52% female), 32 safety signals were identified. Strong associations were observed with antithyroid agents (aSR, 4.18; 95% CI: 1.66–11.95), parathyroid hormones (aSR, 3.09; 95% CI: 1.56–6.44), haematopoietic agents (aSR, 2.55; 95% CI: 1.07–6.49) and meglitinides (aSR, 2.37; 95% CI: 1.15–5.35). While many signals aligned with prior clinical trial data, novel associations with antithyroid and parathyroid agents were discovered.

Conclusion

In our study, we detected 32 safety signals for roflumilast, including notable associations with antithyroid agents and parathyroid hormones. Future investigations using more robust study designs are warranted to evaluate those signals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzamidesPhosphodiesterase 4 InhibitorsPharmacovigilanceAminopyridinesPulmonary Disease, Chronic ObstructiveHumansMaleFemaleAgedMiddle AgedCyclopropanesAdverse Drug Reaction Reporting SystemsHigh-Throughput Screening AssaysDatabases, FactualUnited StatesAlgorithmsAdultAged, 80 and over

Stichwörter der Autor:innen

drug safetypharmacovigilancereal‐world evidenceroflumilastsequence symmetry analysis

Substanzen

RoflumilastBenzamidesPhosphodiesterase 4 InhibitorsAminopyridinesCyclopropanes

Autor:innen und Institutionen

  • Department of Pharmacy Systems, Outcomes and Policy, College of Pharmacy, University of Illinois Chicago, Chicago, Illinois, USA.
  • Department of Medicine, Division of Pulmonary, Critical Care, Sleep, and Allergy, University of Illinois Chicago, Chicago, Illinois, USA.

ORCID-Profile: Abdullah Abdelaziz

Zitieren

APA

Abdelaziz, A., Gaber, C. E., Gupta, P., & Lee, T. A. (2025). High Throughput Pharmacovigilance Screening for Roflumilast Adverse Effects in Real‐World Settings: A Sequence Symmetry Analysis. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70038

Vancouver

Abdelaziz A, Gaber CE, Gupta P, Lee TA. High Throughput Pharmacovigilance Screening for Roflumilast Adverse Effects in Real‐World Settings: A Sequence Symmetry Analysis. Basic & Clinical Pharmacology & Toxicology. 2025. doi:10.1111/bcpt.70038

BibTeX
@article{Abdelaziz2025,
  author = {Abdelaziz, Abdullah and Gaber, Charles E and Gupta, Preeti and Lee, Todd A},
  title = {High Throughput Pharmacovigilance Screening for Roflumilast Adverse Effects in Real‐World Settings: A Sequence Symmetry Analysis},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2025},
  doi = {10.1111/bcpt.70038}
}
Kostenlos starten →